Inflammatory Bowel Disease
The IBD Clinical Trials Team conducts clinical trials of new drugs for patients with inflammatory bowel diseases, including Crohn’s Disease, Ulcerative Colitis and related conditions.
ABTECT-1: A potential new treatment for UC
The ABTECT-1 Study is being done to learn more about an investigational medication, called Obefazimod or 'ABX464', and its effect in people with ulcerative colitis (UC). UC causes inflammation in the lining of the colon (large intestine). The main symptoms of UC are pain and recurring diarrhoea, which may contain blood and/or mucus.
ALAMERE - A potential new treatment for Eosinophilic Esophagitis (EoE)
A potential new treatment for ulcerative colitis (ATLAS-UC)
Do you have Eosinophilic Esophagitis and difficulty swallowing?
A multicentre study of the safety and effectiveness of CC-93538 in adolescent and adult participants with Eosinophilic Esophagitis
COLLECTiVE202 - A potential new oral treatment for UC
A new treatment for Eosinophilic Esophagitis
A study of the safety and effectiveness of tezepelumab in adolescent and adult participants with Eosinophilic Esophagitis
EMERALD2 - A new treatment for Ulcerative Colitis
A phase 2b study to evaluate MORF-057 in adults with moderately to severely active ulcerative colitis (UC).
FUZION - A potential treatment for Fistulizing, Perianal Crohn’s Disease
FUZION: Efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn’s Disease
ILLUMINATE - A potential treatment for Celiac Disease
Palekona - An oral treatment for Ulcerative Colitis
Study of GS-5290 in participants with moderately to severely active ulcerative colitis